Actively Recruiting
Evaluating ctDNA Analysis in Archived Plasma Samples to Guide Adjuvant Treatment in Early-Stage Epithelial Ovarian Cancer
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2026-09-11
50
Participants Needed
1
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of circulating tumor DNA ctDNA to assess minimal residual disease MRD in patients with epithelial ovarian cancer EOC. This observational study focuses on early-stage EOC patients who have undergone surgery with no visible residual disease. The goal is to understand how ctDNA levels before and after surgery relate to cancer recurrence risk and progression-free survival, as current standard care has limitations in predicting outcomes for these patients. The study will analyze stored plasma samples collected before surgery and 4 to 7 weeks after surgery from 50 patients with epithelial ovarian cancer excluding the mucinous subtype. ctDNA will be measured using advanced next-generation sequencing combining genomic and epigenomic data. Laboratory analysis will be done by a specialized company, while clinical data analysis will be performed by the promoting center. The main focus is on whether ctDNA is cleared after surgery, with secondary analyses examining links between ctDNA and tumor features as well as patient outcomes. Participants involvement is retrospective, using previously collected plasma samples and clinical data from other studies. Researchers will compare ctDNA detectability before and after surgery and assess associations with clinical characteristics and survival outcomes. The primary measurement is ctDNA clearance. The study does not involve new treatments or interventions and aims to improve future personalized treatment decisions. The study is expected to complete by February 2027.
CONDITIONS
Brief Title
Setting Up ctDNA Analysis on Archived Plasma Samples
Research Team
C
Camilla Nero, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here